News from ptc therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 23, 2014, 08:00 ET

PTC Therapeutics Begins Rolling NDA Submission to the FDA for Translarna to Treat Duchenne Muscular Dystrophy

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United...

Dec 19, 2014, 08:00 ET

Translarna Granted Orphan Drug Designation in the U.S. and Europe for the Treatment of Mucopolysaccharidosis I

 PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency...

Dec 17, 2014, 16:30 ET

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2014 it approved non-statutory stock options to purchase an...

Dec 03, 2014, 08:00 ET

PTC Therapeutics Announces Launch of Translarna™ (ataluren) in Germany

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) is now commercially available to patients in Germany,...

Nov 21, 2014, 08:00 ET

PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award

 PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that the 2014 Legend of Technology Award for Vision, Innovation, and Leadership has...

Nov 19, 2014, 08:00 ET

Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial in Patients with SMA

 PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the...

Nov 17, 2014, 16:30 ET

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on November 14, 2014 it approved non-statutory stock options to purchase an...

Nov 17, 2014, 08:00 ET
PTC Therapeutics logo

PTC Therapeutics Appoints Dr. Tuyen Ong SVP, Head of Clinical Development and Translational Research

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Tuyen Ong, M.D., MRCOphth, MBA, as Senior Vice President, Head of Clinical...

Nov 14, 2014, 08:00 ET

PTC Therapeutics Recognized for Outstanding Innovation at the 2014 Rare & Orphan Advocacy and Research (ROAR) Awards

 PTC Therapeutics, Inc. (NASDAQ: PTCT) received the Outstanding Innovation Award at The 2014 Rare & Orphan Advocacy & Research Awards...

Nov 13, 2014, 17:15 ET

PTC Therapeutics to Webcast Upcoming Science Day and Investor Conferences

 PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it will hold its 2nd Annual Science Day on Monday, November 24, 2014 from 8:00 a.m....

Nov 06, 2014, 08:00 ET

PTC Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ended September...

Nov 03, 2014, 16:30 ET

PTC Therapeutics Expands Access For Translarna™ (Ataluren)

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been approved to be included in the list of drugs...

Oct 29, 2014, 08:00 ET

PTC Therapeutics to Present at the Credit Suisse 23rd Annual Healthcare Conference

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Credit Suisse 23rd Annual...

Oct 27, 2014, 08:00 ET

Translarna™ Phase 2b Data Published in Muscle & Nerve

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of data and related analysis which provide strong support for concluding that...

Oct 23, 2014, 16:30 ET

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2014 Financial Results

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2014...

Oct 09, 2014, 18:35 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Announces Pricing of Public Offering of Common Stock

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the pricing of an underwritten public offering of 3,000,000 shares of its common stock...

Oct 08, 2014, 16:25 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Announces Proposed Public Offering of Common Stock

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it is commencing an underwritten public offering of 3,000,000 shares of its common stock...

Sep 24, 2014, 16:35 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics to Present at the Leerink Partners Rare Disease Roundtable

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Leerink Partners Rare Disease...

Sep 24, 2014, 16:30 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 23, 2014 it approved non-statutory stock options to purchase an...

Sep 17, 2014, 08:00 ET
PTC Therapeutics logo. (PRNewsFoto/PTC Therapeutics, Inc.)

PTC Therapeutics Expands Global Presence in Support of Translarna™ Launch in Duchenne Muscular Dystrophy

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its global presence with the addition of key executives to leadership...